Navigating a paradigm shift; food and drug administration approved Tarlatamab-dlle redefining the landscape of small cell lung cancer therapy

Abstract

Small cell lung cancer (SCLC) constitutes 10% of lung cancer. It is the leading cause of death due to cancer in men and the second most prevalent cause of cancer related death in women worldwide. It is an extremely hostile tumor with early development, spread, and fatal as it is typically found too late. Early-stage patients are usually treated with chemotherapy and thoracic radiation and surgery is rarely used to treat this malignancy. The addition of immunotherapy to first-line chemotherapy has improved survival for the first time in the decennary. It has demonstrated promise in producing significant, long-lasting responses. The disease is still challenging to treat but adding radiation therapy to a patient's care at certain intervals may enhance illness control. Platinum-based chemotherapy is initially quite effective, eliciting prompt and often substantial responses, however, they are transient effects, and when SCLC recurs, treatment resistance is strong.